What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?

EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)

EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC

EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC

EP: 4.Ongoing Research in BCG-Unresponsive NMIBC

Now Viewing

EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?

EP: 6.Emerging Agents in BCG-Unresponsive NMIBC

EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC

This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.

Shore discusses advantages of the TAR-200 drug delivery device for treating high-risk non–muscle invasive bladder cancer (NMIBC). The device is user friendly for physicians and patients and similar in complexity to placing a urinary catheter. As a sustained-release platform, TAR-200 avoids challenges with standard intravesical chemotherapy related to bladder capacity and retention. The current TAR-200 formulation delivers gemcitabine, known to have antitumor effects based on intravesical and systemic chemotherapy studies. Other drugs like erdafitinib are being tested (TAR-210).

If 1- to 2-year durability is proven, TAR-200 could help patients avoid cystectomy, which is preferable given morbidity and life impact. For high-risk NMIBC, the goal remains preventing progression to more advanced disease in a window where micrometastatic spread may occur.

Video synopsis is AI generated and reviewed by Urology Times® editorial staff.